DUBLIN, Nov. 21, 2014 /PRNewswire/ --Research and Markets has announced the addition of the "China Recombinant Protein Drug Industry Report, 2014-2017" report to their offering.
The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.
The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.
However, as compared with products from leading bio-pharmaceutical enterprises in the United States and Europe, domestic recombinant protein drugs are still characterized by low-end technologies and largely remain in common short-acting areas. And foreign brands still prevail in the markets of recombinant insulin, rhIFN, recombinant coagulation factor and recombinant human follicle-stimulating hormone (rhFSH).
1. Recombinant Insulin Market. In 2013,foreign brands such asNovo Nordisk's insulin aspart and insulin detemir, Sanofi's insulin glargine, Eli Lilly's insulin lispro accounted for 91.4% of recombinant insulin market of Chinese sample hospitals, while domestic insulin e.g. insulin glargine and insulin lispro of Gan & Lee Pharmaceuticals, recombinant insulin of Tonghua Dongbao Pharmaceuticaland animal insulin of Wanbang Biopharmaceuticalswas at a distinct disadvantage, whereas insulin analog products of Gan & Lee are still in the process of development, with huge potential for growth in the future.
2. rhIFN-aMarket.Roche's PEG-IFNa-2a, MSD's PEG-IFNa-2a and IFN-a-2a, and other imported products still dominate Chinese interferon market, sweeping as much as 70.7% of recombinant interferon market of sample hospitals in 2013; whilemore than a dozen local companies like Shanghai Huaxin High Biotechnology Inc., Beijing Tri-Prime Genetic Engineering Co., Ltd. and Anhui Anke Biotechnology (Group) Co., Ltd.mainly produce ordinary short-acting products, which lack strong competitiveness compared with PEG-Intron products (long-acting interferon)with better anti-hepatitisvirus effect.
Moreover, there is no domestic recombinant protein drug in such markets as rhIFN-ß, rhFSH, recombinant coagulation factor VIIa and factorVIIIyet.
Based on support from favorable policies, R&D ability enhancement as well as being optimistic about market prospects, a large number of biotech companies are vigorously developing long-acting, high-end protein drugs.
Key Topics Covered:
1. Overview of Recombinant Protein Drug Industry
2. Development of Recombinant Protein Drugs in China
3. Recombinant Protein Drug Market Segments in China
4. Major Recombinant Protein Companies in China
5. Summary and Forecast
- 3SBio Inc.
- Anhui Anke Biotechnology (Group) Co., Ltd.,
- Beijing SL PHarmaceutical Co., Ltd.
- Changchun High & New Technology Industry (Group) Inc.
- Essex Bio-Technology Limited
- Jiangsu Shihuan Bioengineering Co., Ltd.
- Livzon Pharmaceutical Group Inc.
- Shenzhen Neptunus Interlong Bio-Technique Co., Ltd.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Uni-Bio Science Group Limited
For more information visit http://www.researchandmarkets.com/research/zs8mct/china_recombinant
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets